Abstract
Eukaryotic elongation factor 2 (eEF2), a key regulator of protein synthesis, is involved in the progression of several types of cancer. This first study was to investigate the relationships between eEF2 protein and prostate cancer (PCa). Immunohistochemical staining was used to verify eEF2 protein in a set of 97 formalin-fixed, paraffin-embedded primary PCa tissues. Expression of eEF2 protein in positive cells was characterized by cytoplasmic staining. Correlations with clinicopathological factors were evaluated by Chi-square or Fisher’s exact probability tests. eEF2 protein was found in 74 out of 97 (76.29%) patients. eEF2-positive had higher PSA and Gleason score than negative in all patients. In addition, the positive expression of eEF2 protein was significantly associated with PSA and Gleason score (P = 0.007 and 0.002). However, no significant correlations occurred between expression of eEF2 protein and TNM stage (P = 0.292). In those eEF2 protein-positive patients, we have found staining intensity of eEF2 protein was not only associated with PSA and Gleason score, but also associated with TNM stage (P = 0, 0.014 and 0.001, respectively). To conclude, our study indicates that expression of eEF2 protein is a potential biomarker for evaluating PCa.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30
Zhu Y, Wang HK, Qu YY, Ye DW (2015) Prostate cancer in East Asia: evolving trend over the last decade. Asian J Androl 17:48–57
Sundi D, Schaeffer EM (2016) Progress in prognosis and prediction for men with prostate cancer. Eur Urol 22:30761–30768
Grzmil M, Hemmings BA (2012) Translation regulation as a therapeutic target in cancer. Cancer Res 72:3891–3900
Tash JS, Chakrasali R, Jakkaraj SR, Hughes J, Smith SK, Hornbaker K, Heckert LL, Ozturk SB, Hadden MK, Kinzy TG, Blagg BS, Georg GL (2008) Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1(HSP90BETA) and EEF1A (eEF1A) and stimulates II 1a transcription in rat sertoli cells. Biol Reprod 78:1139–1152
Tomlison VA, Newbery HJ, Wray NR, Jackson J, Larionov A, Miller WR, Dixon JM, Abbott CM (2005) Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumors. BMC Cancer 5:113–119
Nakamura J, Aoyagi S, Nanchi I, Nakatsuka S, Hirata E, Shibata S, Fukuda M, Yamamoto Y, Fukuda I, Tatsumi N, Ueda T, Fujiki F, Nomura M, Nishida S, Shirakata T, Hosen N, Tsuboi A, Oka Y, Nezu R, Mori M, Doki Y, Aozasa K, Sugiyama H, Oji Y (2009) Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle. Int J Oncol 34:1181–1189
Oji Y, Tatsumi N, Fukuda M, Nakatsuka S, Aoyagi S, Hirata E, Nanchi I, Fujiki F, Nakajima H, Yamamoto Y, Shibata S, Nakamru M, Hasegawa K, Takagi S, Fukada I, Hoshikawa T, Murakami Y (2014) The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers. Int J Oncol 44:1461–1469
Sun HG, Dong XJ, Lu T, Yang MF, Wang XM (2014) Clinical value of eukaryotic elongation factor 2 in non-small cell lung cancer patients. Asian Pac J Cancer Prev 14:6533–6535
Tan HY, Wang N, Tsao SW, Zhang Z, Feng Y (2014) Suppression of vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 by alkaloids in coptidis rhizome in hepatocellular carcinoma. Integr Cancer Ther 13:425–434
Rhoads RE (1991) Protein synthesis, cell growth and oncogenesis. Curr Opin Cell Biol 3:1019–1024
Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, Collins C, Gray JW, Diebold J, Demetrick DJ, Lee JM (2002) Protein elongation factor eEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 31:301–305
Yoshizawa A, Fukuoka J, Shimizu S, Shimizu S, Shilo K, Franks TJ, Hewitt SM, Fujii T, Cordon-cardo C, Jen J, Travis WD (2010) Overexpression of phosphor-eIF4E is associated with survival through AKT pathway in on-small cell lung cancer. Clin Cancer Res 16:240–248
Pinke DE, Kalloger SE, Francetic T, Huntsman DG, Lee JM (2008) The prognostic significance of elongation factor eEF1A2 on ovarian cancer. Gynecol Oncol 108:561–568
Hagner PR, Schneider A, Gartenhaus RB (2010) Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 115:2127–2135
Chen CY, Fang HY, Chiou SH, Yi SE, Huang CY, Chiang SF, Chang HW, Lin TY, Chiang IP, Chow KC (2011) Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells. Cancer Sci 102:1582–1589
Bilanges B, Stokoe D (2007) Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. Oncogene 26:5973–5970
Wang N, Feng YB, Tan HY, Cheung F, Hong M, Lao L, Nagamatsu T (2015) Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation huanglian-jiedu decoction in human hepatocellular carcinoma. J Ethnopharmacol 164:309–318
Nowroozi MR, Momeni SA, Ohadian Moghadam S, Ayati E, Mortazavi A, Arfae S, Jamshidian H, Taherimahmoudi M, Ayati M (2016) Prostate-specific antigen density and Gleason score predict adverse pathologic features in patients with clinically localized prostate cancer. Nephrourol Mon 8:39984–39987
Kgatle MM, Kalla AA, Islam MM, Sathekge M, Moorad R (2016) Prostate cancer: epigenetic alterations, risk factors, and therapy. Prostate Cancer 6:435–445
Acknowledgements
Thank all patient’s participation and grant from the National Natural Science Foundation of China (81272839) and the Jiangsu Province’s Key Medical Talents Program (RC2011108).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of First Affiliated Hospital of Suzhou University’s research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Zhang, X., Hu, L., Du, M. et al. Eukaryotic Elongation Factor 2 (eEF2) is a Potential Biomarker of Prostate Cancer. Pathol. Oncol. Res. 24, 885–890 (2018). https://doi.org/10.1007/s12253-017-0302-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-017-0302-7